Overactive Bladder Features

CME Articles

Shared Decision Making in Managing Idiopathic and Neurogenic OAB

Communicating effectively about appropriate options and eliciting patient input for overactive bladder (OAB) can improve outcomes.

Latest Overactive Bladder News

Overactive Bladder Medications Only Slightly Beneficial

Overactive Bladder Medications Only Slightly Beneficial

Small reductions in urge incontinence episodes, voids per day with daily dose of medications.

OAB Drugs Prescribed Less Frequently to Men

OAB Drugs Prescribed Less Frequently to Men

A study found that 33.8% of women received anticholinergics compared with 19.4% of men.

Overactive Bladder Increases Falling Risk in the Elderly

Overactive Bladder Increases Falling Risk in the Elderly

OAB treatment is associated with a decreased risk of falls, study finds.

OAB, SUI Worse After Vaginal Birth

OAB, SUI Worse After Vaginal Birth

Regardless of delivery type, obesity ups the risk of more severe urinary symptoms, study shows.

Overactive Bladder Found to Raise Nocturia Risk

Overactive Bladder Found to Raise Nocturia Risk

In a study, severe nocturia predicted increased mortality risk.

Combined High-Dosage Drugs Shown to Ease Resistant OAB

Elderly patients with OAB may benefit from combined high-dosage antimuscarinics.

Repeat BTXA Injections Okay for Non-Neurogenic OAB

Repeat injections of onabotulinumtoxinA (BTXA) appear to benefit patients with non-neurogenic overactive bladder.

Stubborn Overactive Bladder Responds to Sacral Neuromodulation

Improvements in efficacy and quality of life last at least six months, study finds.

Nocturia Bidirectionally Linked with Depression

Nocturia Bidirectionally Linked with Depression

Depression risk greater for men with nocturia than for women with nocturia.

Desmopressin Effective for Nocturia in Women

Desmopressin Effective for Nocturia in Women

Two studies show significant reduction in number of nocturnal voids for women.

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

Percutaneous Tibial Nerve Stimulation Has Lasting Benefit

In most responders, overactive bladder symptom improvement sustained to three years.

FDA: Phony Botox Purveyors Targeting U.S. Practices

FDA: Phony Botox Purveyors Targeting U.S. Practices

Products advertised through fax; not FDA approved.

FDA Approves 1st OTC Drug for Women With Overactive Bladder

FDA Approves 1st OTC Drug for Women With Overactive Bladder

Oxytrol is intended for use by those 18 and older.

Increasing Solifenacin Dose Can Improve Outcomes in Severe OAB

Increasing the daily dose from 5 to 10 mg resulted in reductions in mean total urgency score and mean micturition frequency.

FDA Approves Botox for Overactive Bladder

The FDA has approved onabotulinumtoxinA (Botox) as a treatment for overactive bladder (OAB) in adults who are inadequately managed with anticholinergic medications.